UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Sillajen likely to scrap global P3 trials for Pexa-Vec
Sillajen is in danger of aborting its phase 3 clinical trial for Pexa-Vec (...
by Lee Han-soo
|
2019-08-02 10:29
라인
KAIST-Hanyang University team presents new anticancer principle
Researchers at Korea Advanced Institute of Science & Technology (KAIST) and...
by Lee Han-soo
|
2019-08-01 17:30
라인
Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia
Novartis Korea’s Revolade (ingredient: eltrombopag) will receive reimbursem...
by Lee Han-soo
|
2019-08-01 13:36
라인
New weight loss drug Qsymia wins local approval
The local drug regulator has approved a new obesity treatment, Qsymia Cap. ...
by Lee Hye-seon
|
2019-08-01 10:57
라인
‘Hanmi’s Carnitil improves cognitive function in patients’
Hanmi Pharmaceutical said that it has presented the phase 4 clinical trial ...
by Lee Han-soo
|
2019-07-31 17:05
라인
Hanall marks record sales in Q2
Hanall Biopharma said that it registered record-breaking sales and operatin...
by Lee Han-soo
|
2019-07-31 17:00
라인
Novartis fails to expand heart failure drug Entresto’s indication
Novartis said its phase-3 Paragon-HF trial on heart failure treatment Entre...
by Kim Yun-mi
|
2019-07-31 14:26
라인
Hanmi marks ₩270.4 billion in Q2 sales
Hanmi Pharmaceutical said Tuesday that it recorded sales of 270.4 billion w...
by Lee Han-soo
|
2019-07-30 17:26
라인
Kolmar Korea boosts beauty, health biz through acquisitions
Kolmar Korea Holdings, having units in cosmetics, pharmaceuticals, and heal...
by Park Gi-taek
|
2019-07-30 14:43
라인
GC’s Chinese partner applies for Hunter syndrome drug’s sales approval
GC said that CANBridge Pharmaceuticals, its Chinese partner, has applied fo...
by Lee Han-soo
|
2019-07-30 10:49
라인
‘FDA likely to OK 11 blockbuster candidates in August’
The U.S. Food and Drug Administration (FDA) will likely approve 11 innovati...
by Kim Yun-mi
|
2019-07-29 16:55
라인
Top-30 makers produce more than half of drugs
Drug output by 30 largest pharmaceutical companies accounted for 54 percent...
by Lee Hye-seon
|
2019-07-29 16:38
라인
Takeda’s Zejula poised to change local ovarian cancer treatment market
Takeda’s Zejula (ingredient: niraparib) became eligible for an insurance be...
by Kim Yun-mi
|
2019-07-29 12:04
라인
Court extends ‘temporary suspension’ of order to cancel Invossa trials
A local court has decided to temporarily suspend the legal effect of an adm...
by Jeong Sae-im
|
2019-07-26 17:50
라인
SNUBH professor is 1st Asian keynoter at international Alzheimer meet
Professor Kim Sang-yun of Seoul National University Bundang Hospital has be...
by Lee Han-soo
|
2019-07-26 16:08
라인
‘Kolon Life Science to start following up on Invossa-treated patients’
Kolon Life Science will conduct the first test on patients who received Inv...
by Lee Han-soo
|
2019-07-26 12:21
라인
JW Creagene wins US patent for making dendritic cell treatment
JW Creagene said Thursday that it has obtained a patent for its source tech...
by Lee Han-soo
|
2019-07-25 16:39
라인
Merck, Pfizer launch metastatic merkel cell carcinoma treatment in Korea
Merck and Pfizer will address the unmet medical need of patients suffering ...
by Lee Han-soo
|
2019-07-25 15:18
라인
[Focus] Korean biopharmas eye US Humira market
Samsung Bioepis’s Humira biosimilar has secured entry into the U.S. market....
by Jeong Sae-im
|
2019-07-25 15:02
라인
Kolon Life Science ends Invossa deal with Hong Kong partner
Kolon Life Science said it has terminated the supply agreement of Invossa-K...
by Lee Han-soo
|
2019-07-25 11:17
-
이전
31
32
33
34
35
36
37
38
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top